Gary Hogge: Yeah, so obviously there’s a lot of news and buzz around the BCVA and cutting in looking at three line loss over time. The good thing is, is that we, we examined it closely throughout and, and, and the cohort four, which is the applicable population that is involved in those studies. For the MO we haven’t had a three line loss in any part of cohort four patients, so that, that’s certainly something to be intrigued about. Smaller numbers we know. But it looks like, we’ve maintained that those visual improvements that we observed over time and reported out and the data coming up on at ARVO will focus on looking at different analysis of the OPC assessment and how quickly those changes occur and how they tie into the visual acuity improvements, particularly in those patients that showed signs of auto retinal structural improvement. And so we’re very excited to have those data again presented by an entirely independent analysis.
William Wood: Appreciate that extra color there. And then also, just to clarify, do you know the timing of the release of ARVO abstracts? And then whether you expect that the abstract presenter may comment on the Phase2 enrollment status since there’s a meaningful overlap in trial sites there?
Gary Hogge: Yeah, so the, per the ARVO website there will be available sometime in early March so perhaps the next week or two with regards to Dr. Benin and his ability to comment on the future or the ongoing study that’s conducted by Genentech Roche, I don’t think he’ll be able to offer any additional comments at this time.
Brian Culley: And William, I’m going to add here. I don’t think I’m putting Roche on the spot, but as a general matter, when we were running the Phase 1/2a, these were the first 24 people on the planet to ever receive this experimental therapy. Now that there is a basket of safety and efficacy data available, it makes me think that the conversation between a prospective patient on the clinical trial and their doctor might go a little differently because they could actually show some results that are available in the, in the public domain. So I am hopeful, although I have no specific information because the trial is just underway, but I’m hopeful that enrollment will go faster than it was when we were running it.
William Wood: Got it. That’s really helpful. And then one last one, switching gears. In regards to your a and p one, there’s obviously been a number of players in the hearing space, a lot of them incorporating intercom administration. I’m just curious what your plans are on delivering the sales into the inner ear. I know you’ve mentioned that it could be a good combo for cochlear implants, but I don’t think you’re going to be limiting to that. Maybe just walk us through your plans there?
Brian Culley: Yeah, I, so I think what the right way for me to describe is that we have a, a lot of good ideas, but they need to be tested. And so we’re not today in a position to say a whole lot more about an intended patient population or exactly what the right clinical application will be. There are many causes of hearing loss. We’re going to follow the data that’s collected, and right now we’re just at the very earliest stages of that process. So it’s, it’s difficult, but I think as we reject some hypotheses, reject some options and begin to narrow down what we think is the best approach, that will be something we’ll look forward to, to sharing when we are able to do so and feel confident in that information.
Operator: Our next question comes from the line of Kristen Kluska from Cantor Fitzgerald. Please proceed.